Antimicrobial Resistance in Gram-Negative Hospital Isolates: Results of the Turkish Hitit-2 Surveillance Study of 2007
No Thumbnail Available
Date
2009
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis Ltd
Abstract
Resistance rates to amikacin, ciprofloxacin, ceftazidime, cefepime, imipenem, cefoperazone/sulbactam and piperacillin/tazobactam in Escherichia coli (n = 438), Klebsiella pneumoniae (n = 444), Pseudomonas aeruginosa (n = 210) and Acinetobacter baumanni (n =200) were determined with E-test in a multicenter surveillance study (HITIT-2) in 2007. ESBL production in Escherichia coli and K. pneumoniae was investigated following the CLSI guidelines. Overall 42.0% of E.coli and 41.4% of K. pneumoniae were ESBL producers. In E. coli, resistance to imipenem was not observed, resistance to ciprofloxacin and amikacin was 58.0% and 5.5% respectively. In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively. In P. aeruginosa the lowest rate of resistance was observed with piperacillin/tazobactam (18.1%). A. baumanni isolates were highly resistant to all the antimicrobial agents, the lowest level of resistance was observed against cefoperazone/sulbactam (52.0%) followed by imipenem (55.5%). This study showed that resistance rates to antimicrobials are high in nosocomial isolates and show variations among the centers.
Description
Kibar, Filiz/0000-0003-2983-2399; Gur, Deniz/0000-0002-7504-8450; Telli, Murat/0000-0003-2648-881X
Keywords
Antimicrobial Resistance, Esbl, Gram-Negative Bacteria, Beta-Lactamase Inhibitor, E.Coli, K. Pneumoniae, P. Aeruginosa, A. Baumannii
Turkish CoHE Thesis Center URL
WoS Q
Q4
Scopus Q
Q3
Source
Volume
21
Issue
4
Start Page
383
End Page
389